Add
MYGN to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| MYGN > SEC Filings for MYGN > Form 8-K on 22-Jan-2009 | All Recent SEC Filings |
22-Jan-2009
Other Events, Financial Statements and Exhibits
On January 21, 2009, Myriad Pharmaceuticals, Inc., a wholly owned subsidiary of Myriad Genetics, Inc. ("Myriad"), announced that it had acquired the rights and assets to the drug candidate Bevirimat from Panacos Pharmaceuticals, Inc. for a one-time upfront payment of $7 million. Under the purchase agreement, Myriad has obtained all patents, patent applications, product inventories, clinical data, and regulatory filing rights related to the compound. Bevirimat is an HIV maturation inhibitor designed to have activity against a broad range of HIV strains. Bevirimat is currently in a Phase 2b clinical study. Myriad will assume control of all clinical and commercial development going forward.
A copy of the press release announcing the acquisition is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into Item 8.01 of this Current Report on Form 8-K.
(d) Exhibits.
99.1 Press Release dated January 21, 2009.
Page 2 of 4 pages
|
|